-
Published01/09/2026
-
Today05/09/2026
-
Deadline16/09/2026
-
Opening of tenders16/09/2026
Utilities
- indicates text translated automatically in your browsing language
Public procurement of combined diphtheria-tetanus-cellular pertussis, inactivated polio, H. influenzae type b, hepatitis B (DTPa-IPV-HB-HB)-hexavalent vaccine
Note: Not all information for this procedure were successfully computed. Please consult linked documents for more details.
Estimated minimum value excluding VAT: RON 266 032.000,00 Estimated maximum value net of VAT: Frequency of awarding subsequent contracts according to the needs of the contracting authority and the availability of funds necessary for the procurement. The quantity covered by the framework agreement is a minimum of 1,300,000 doses of the combined diphtheria-tetanus-cellular pertussis, inactivated polio, H. influenzae type b, hepatitis B (DTPa-IPV-HB-HB)-hexavalent vaccine and a maximum of 1,800,000 doses of the combined diphtheria-tetanus-cellular pertussis, inactivated polio, H. influenzae type b, hepatitis B (DTPa-IPV-HB-HB)-hexavalent vaccine. The amount that could be the subject of a subsequent contract is at least 325,000 doses, and the maxine amount is 450,000 doses. Estimated value of the largest subsequent contract: 92,088,000,00 lei without VAT
https://www.e-licitatie.ro
https://www.e-licitatie.ro
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.